Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Buy
60
OMCL Quote, Financials, Valuation and Earnings
Last price:
$50.73
Seasonality move
:
-0.06%
Day range:
$49.93 - $51.30
52-week range:
$22.66 - $51.30
Dividend yield:
0%
P/E ratio:
119.00x
P/S ratio:
2.01x
P/B ratio:
1.87x
Volume:
460.2K
Avg. volume:
610.3K
1-year change:
17.75%
Market cap:
$2.3B
Revenue:
$1.1B
EPS (TTM):
$0.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OMCL
Omnicell, Inc.
|
$313.4M | $0.50 | 4.38% | 46.78% | $54.00 |
|
AMS
American Shared Hospital Services
|
$8.8M | $0.02 | -3.19% | -100% | $4.50 |
|
ASTH
Astrana Health, Inc.
|
$930.5M | $0.33 | 39.88% | 82.8% | $36.8889 |
|
CCEL
Cryo-Cell International, Inc.
|
$7.7M | -$0.09 | -4.04% | -60.92% | $8.50 |
|
CCLD
CareCloud, Inc.
|
$32.1M | $0.11 | 13.67% | 18233.33% | $6.31 |
|
TXG
10X Genomics, Inc.
|
$156M | -$0.06 | -5.46% | -85.12% | $17.93 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OMCL
Omnicell, Inc.
|
$50.74 | $54.00 | $2.3B | 119.00x | $0.00 | 0% | 2.01x |
|
AMS
American Shared Hospital Services
|
$2.18 | $4.50 | $14.2M | 11.73x | $0.00 | 0% | 0.49x |
|
ASTH
Astrana Health, Inc.
|
$28.4300 | $36.8889 | $1.4B | 149.63x | $0.00 | 0% | 0.48x |
|
CCEL
Cryo-Cell International, Inc.
|
$3.55 | $8.50 | $28.6M | 498.00x | $0.15 | 18.31% | 0.91x |
|
CCLD
CareCloud, Inc.
|
$3.05 | $6.31 | $129.3M | 74.94x | $0.00 | 0% | 0.83x |
|
TXG
10X Genomics, Inc.
|
$20.46 | $17.93 | $2.6B | -- | $0.00 | 0% | 3.94x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OMCL
Omnicell, Inc.
|
14.48% | 0.513 | 15.13% | 1.05x |
|
AMS
American Shared Hospital Services
|
50.05% | 0.193 | 110.57% | 1.02x |
|
ASTH
Astrana Health, Inc.
|
58.37% | -1.141 | 92.2% | 1.34x |
|
CCEL
Cryo-Cell International, Inc.
|
-564.01% | 1.765 | 33.28% | 0.78x |
|
CCLD
CareCloud, Inc.
|
14.33% | 4.091 | 7.63% | 1.05x |
|
TXG
10X Genomics, Inc.
|
9.97% | 3.120 | 5.88% | 3.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OMCL
Omnicell, Inc.
|
$134.5M | $8.2M | 1.22% | 1.6% | 2.65% | $14M |
|
AMS
American Shared Hospital Services
|
$1.6M | $48K | -6.67% | -12.09% | 0.67% | -$2M |
|
ASTH
Astrana Health, Inc.
|
$81.6M | $19.2M | 0.88% | 1.85% | 2.01% | $7.4M |
|
CCEL
Cryo-Cell International, Inc.
|
$5.8M | $1.9M | -20.01% | -- | 24.29% | $2.5M |
|
CCLD
CareCloud, Inc.
|
$10.8M | $3.6M | 19.45% | 21.2% | 11.65% | $5.7M |
|
TXG
10X Genomics, Inc.
|
$100.9M | -$32.2M | -9.26% | -10.32% | -21.64% | $33.9M |
Omnicell, Inc. vs. Competitors
-
Which has Higher Returns OMCL or AMS?
American Shared Hospital Services has a net margin of 1.76% compared to Omnicell, Inc.'s net margin of -4.59%. Omnicell, Inc.'s return on equity of 1.6% beat American Shared Hospital Services's return on equity of -12.09%.
Company Gross Margin Earnings Per Share Invested Capital OMCLOmnicell, Inc.43.3% $0.12 $1.4B AMSAmerican Shared Hospital Services21.94% -$0.00 $53.2M -
What do Analysts Say About OMCL or AMS?
Omnicell, Inc. has a consensus price target of $54.00, signalling upside risk potential of 6.43%. On the other hand American Shared Hospital Services has an analysts' consensus of $4.50 which suggests that it could grow by 106.81%. Given that American Shared Hospital Services has higher upside potential than Omnicell, Inc., analysts believe American Shared Hospital Services is more attractive than Omnicell, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OMCLOmnicell, Inc.5 2 0 AMSAmerican Shared Hospital Services0 0 0 -
Is OMCL or AMS More Risky?
Omnicell, Inc. has a beta of 0.773, which suggesting that the stock is 22.655% less volatile than S&P 500. In comparison American Shared Hospital Services has a beta of 0.120, suggesting its less volatile than the S&P 500 by 88.028%.
-
Which is a Better Dividend Stock OMCL or AMS?
Omnicell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. American Shared Hospital Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell, Inc. pays -- of its earnings as a dividend. American Shared Hospital Services pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OMCL or AMS?
Omnicell, Inc. quarterly revenues are $310.6M, which are larger than American Shared Hospital Services quarterly revenues of $7.2M. Omnicell, Inc.'s net income of $5.5M is higher than American Shared Hospital Services's net income of -$329K. Notably, Omnicell, Inc.'s price-to-earnings ratio is 119.00x while American Shared Hospital Services's PE ratio is 11.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell, Inc. is 2.01x versus 0.49x for American Shared Hospital Services. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMCLOmnicell, Inc.2.01x 119.00x $310.6M $5.5M AMSAmerican Shared Hospital Services0.49x 11.73x $7.2M -$329K
-
Which has Higher Returns OMCL or ASTH?
Astrana Health, Inc. has a net margin of 1.76% compared to Omnicell, Inc.'s net margin of 0.11%. Omnicell, Inc.'s return on equity of 1.6% beat Astrana Health, Inc.'s return on equity of 1.85%.
Company Gross Margin Earnings Per Share Invested Capital OMCLOmnicell, Inc.43.3% $0.12 $1.4B ASTHAstrana Health, Inc.8.54% $0.01 $1.6B -
What do Analysts Say About OMCL or ASTH?
Omnicell, Inc. has a consensus price target of $54.00, signalling upside risk potential of 6.43%. On the other hand Astrana Health, Inc. has an analysts' consensus of $36.8889 which suggests that it could grow by 29.75%. Given that Astrana Health, Inc. has higher upside potential than Omnicell, Inc., analysts believe Astrana Health, Inc. is more attractive than Omnicell, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OMCLOmnicell, Inc.5 2 0 ASTHAstrana Health, Inc.8 2 0 -
Is OMCL or ASTH More Risky?
Omnicell, Inc. has a beta of 0.773, which suggesting that the stock is 22.655% less volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.424%.
-
Which is a Better Dividend Stock OMCL or ASTH?
Omnicell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell, Inc. pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OMCL or ASTH?
Omnicell, Inc. quarterly revenues are $310.6M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. Omnicell, Inc.'s net income of $5.5M is higher than Astrana Health, Inc.'s net income of $1.1M. Notably, Omnicell, Inc.'s price-to-earnings ratio is 119.00x while Astrana Health, Inc.'s PE ratio is 149.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell, Inc. is 2.01x versus 0.48x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMCLOmnicell, Inc.2.01x 119.00x $310.6M $5.5M ASTHAstrana Health, Inc.0.48x 149.63x $956M $1.1M
-
Which has Higher Returns OMCL or CCEL?
Cryo-Cell International, Inc. has a net margin of 1.76% compared to Omnicell, Inc.'s net margin of 9.58%. Omnicell, Inc.'s return on equity of 1.6% beat Cryo-Cell International, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OMCLOmnicell, Inc.43.3% $0.12 $1.4B CCELCryo-Cell International, Inc.74.61% $0.09 -$2.2M -
What do Analysts Say About OMCL or CCEL?
Omnicell, Inc. has a consensus price target of $54.00, signalling upside risk potential of 6.43%. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 139.44%. Given that Cryo-Cell International, Inc. has higher upside potential than Omnicell, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than Omnicell, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OMCLOmnicell, Inc.5 2 0 CCELCryo-Cell International, Inc.0 1 0 -
Is OMCL or CCEL More Risky?
Omnicell, Inc. has a beta of 0.773, which suggesting that the stock is 22.655% less volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.12%.
-
Which is a Better Dividend Stock OMCL or CCEL?
Omnicell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 18.31% to investors and pays a quarterly dividend of $0.15 per share. Omnicell, Inc. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.
-
Which has Better Financial Ratios OMCL or CCEL?
Omnicell, Inc. quarterly revenues are $310.6M, which are larger than Cryo-Cell International, Inc. quarterly revenues of $7.8M. Omnicell, Inc.'s net income of $5.5M is higher than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, Omnicell, Inc.'s price-to-earnings ratio is 119.00x while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell, Inc. is 2.01x versus 0.91x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMCLOmnicell, Inc.2.01x 119.00x $310.6M $5.5M CCELCryo-Cell International, Inc.0.91x 498.00x $7.8M $749.4K
-
Which has Higher Returns OMCL or CCLD?
CareCloud, Inc. has a net margin of 1.76% compared to Omnicell, Inc.'s net margin of 9.85%. Omnicell, Inc.'s return on equity of 1.6% beat CareCloud, Inc.'s return on equity of 21.2%.
Company Gross Margin Earnings Per Share Invested Capital OMCLOmnicell, Inc.43.3% $0.12 $1.4B CCLDCareCloud, Inc.34.83% $0.04 $67.5M -
What do Analysts Say About OMCL or CCLD?
Omnicell, Inc. has a consensus price target of $54.00, signalling upside risk potential of 6.43%. On the other hand CareCloud, Inc. has an analysts' consensus of $6.31 which suggests that it could grow by 106.97%. Given that CareCloud, Inc. has higher upside potential than Omnicell, Inc., analysts believe CareCloud, Inc. is more attractive than Omnicell, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OMCLOmnicell, Inc.5 2 0 CCLDCareCloud, Inc.1 1 0 -
Is OMCL or CCLD More Risky?
Omnicell, Inc. has a beta of 0.773, which suggesting that the stock is 22.655% less volatile than S&P 500. In comparison CareCloud, Inc. has a beta of 1.993, suggesting its more volatile than the S&P 500 by 99.347%.
-
Which is a Better Dividend Stock OMCL or CCLD?
Omnicell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CareCloud, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell, Inc. pays -- of its earnings as a dividend. CareCloud, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OMCL or CCLD?
Omnicell, Inc. quarterly revenues are $310.6M, which are larger than CareCloud, Inc. quarterly revenues of $31.1M. Omnicell, Inc.'s net income of $5.5M is higher than CareCloud, Inc.'s net income of $3.1M. Notably, Omnicell, Inc.'s price-to-earnings ratio is 119.00x while CareCloud, Inc.'s PE ratio is 74.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell, Inc. is 2.01x versus 0.83x for CareCloud, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMCLOmnicell, Inc.2.01x 119.00x $310.6M $5.5M CCLDCareCloud, Inc.0.83x 74.94x $31.1M $3.1M
-
Which has Higher Returns OMCL or TXG?
10X Genomics, Inc. has a net margin of 1.76% compared to Omnicell, Inc.'s net margin of -18.44%. Omnicell, Inc.'s return on equity of 1.6% beat 10X Genomics, Inc.'s return on equity of -10.32%.
Company Gross Margin Earnings Per Share Invested Capital OMCLOmnicell, Inc.43.3% $0.12 $1.4B TXG10X Genomics, Inc.67.71% -$0.22 $872.1M -
What do Analysts Say About OMCL or TXG?
Omnicell, Inc. has a consensus price target of $54.00, signalling upside risk potential of 6.43%. On the other hand 10X Genomics, Inc. has an analysts' consensus of $17.93 which suggests that it could fall by -12.37%. Given that Omnicell, Inc. has higher upside potential than 10X Genomics, Inc., analysts believe Omnicell, Inc. is more attractive than 10X Genomics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OMCLOmnicell, Inc.5 2 0 TXG10X Genomics, Inc.4 12 0 -
Is OMCL or TXG More Risky?
Omnicell, Inc. has a beta of 0.773, which suggesting that the stock is 22.655% less volatile than S&P 500. In comparison 10X Genomics, Inc. has a beta of 2.183, suggesting its more volatile than the S&P 500 by 118.314%.
-
Which is a Better Dividend Stock OMCL or TXG?
Omnicell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 10X Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell, Inc. pays -- of its earnings as a dividend. 10X Genomics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OMCL or TXG?
Omnicell, Inc. quarterly revenues are $310.6M, which are larger than 10X Genomics, Inc. quarterly revenues of $149M. Omnicell, Inc.'s net income of $5.5M is higher than 10X Genomics, Inc.'s net income of -$27.5M. Notably, Omnicell, Inc.'s price-to-earnings ratio is 119.00x while 10X Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell, Inc. is 2.01x versus 3.94x for 10X Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMCLOmnicell, Inc.2.01x 119.00x $310.6M $5.5M TXG10X Genomics, Inc.3.94x -- $149M -$27.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
